Zotemtegrast Drug Asset Due Diligence Report 2026

This Zotemtegrast Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Zotemtegrast can convert its Small molecule drug profile and α4β7 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zotemtegrast (query alias: Zotemtegrast)
Modality / target	Small molecule drug; α4β7; α4β7 antagonists
Highest global status	Phase 2
Originator	Morphic Therapeutic, Inc.
Active developers	Morphic Therapeutic, Inc., Eli Lilly Suzhou Pharmaceutical Co. Ltd., Eli Lilly & Co.

The MCP disease footprint includes Ulcerative colitis, active moderate, Ulcerative colitis, active severe, Crohn Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07707375	Phase 1	Recruiting	50	Primary endpoint not disclosed in English source
NCT07415044	Phase 2	Recruiting	1431	Primary endpoint not disclosed in English source
NCT07186101	Phase 2	Recruiting	252	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)

Phase 2; n=280; evaluation: Not stated in English source. Reported fields: Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) = 31.9 % ; Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS) = 23.9 %

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1)

Phase 2; n=39; evaluation: Not stated in English source. Reported fields: Main Cohort: Change From Baseline to Week 12 in the Robarts Histopathology Index (RHI) Score(Mean) = -6.4 Point ; Other (Not Including Serious) Adverse Events = 4 Pts

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: RHI = -6.4 Point Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zotemtegrast addresses Ulcerative colitis, active moderate, Ulcerative colitis, active severe, Crohn Disease. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-07-08	Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease	Phase 2	US$3,200.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO